Advanced Magnetics, Inc. Announces Common Stock Offering
March 06 2006 - 10:00PM
PR Newswire (US)
CAMBRIDGE, Mass., March 6 /PRNewswire-FirstCall/ -- Advanced
Magnetics, Inc. (AMEX:AVM) announced that today it priced an
offering of 1,233,214 shares of its common stock resulting in
estimated net proceeds of approximately $31.7 million after
deducting fees and commissions and estimated offering expenses
associated with the offering. ThinkEquity Partners LLC is acting as
the sole book runner for this offering. The proceeds from the
transaction will be used to fund clinical development programs,
including continued development of ferumoxytol as an iron
replacement therapeutic, and for general working capital purposes.
The securities were issued pursuant to the Company's existing shelf
registration statement on Form S-3 and a registration statement
filed pursuant to Rule 462(b) promulgated under the Securities Act
of 1933, as amended. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy the securities
in this offering, nor shall there be any sale of these securities
in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state. This offering of shares of
common stock may be made only by means of a prospectus supplement
and accompanying prospectus. Copies of the prospectus supplement
and the accompanying prospectus, when available, can be obtained
from the SEC's website at http://www.sec.gov/. About Advanced
Magnetics Advanced Magnetics, Inc. is a developer of
superparamagnetic iron oxide nanoparticles used in pharmaceutical
products. As a leader in our field, we are dedicated to the
development and commercialization of our proprietary nanoparticle
technology for use in therapeutic iron compounds to treat anemia,
as well as novel imaging agents to aid in the diagnosis of
cardiovascular disease and cancer. For more information about us,
please visit our website at http://www.advancedmagnetics.com/, the
content of which is not part of this press release. This document
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and federal
securities laws. Any statements contained in this press release
that do not describe historical fact, including statements
regarding the clinical development of ferumoxytol and our intended
use of the proceeds from the financing are forward-looking
statements that involve risks and uncertainties that could cause
actual results to differ materially from those discussed in such
forward-looking statements. Such risks and uncertainties include
the following: (1) the possibility that we may not be able to
successfully complete the clinical development of ferumoxytol, or
may not be able to complete the development in a timely or
cost-effective manner, due to the timing of enrollment of patients
in the Phase III studies, unexpected results from our clinical
sites, inadequate performance by third-party service providers
involved in the conduct of the clinical trials, deficiencies in the
design or oversight by us of these trials, or any other factor
causing an increase in expenses, a delay and/or a negative effect
on the results of the clinical studies for ferumoxytol; (2)
uncertainties surrounding the timing and results of FDA
interactions regarding the clinical development of ferumoxytol and
our ability to obtain regulatory approval for ferumoxytol from the
FDA; (3) the possibility that the results of past ferumoxytol
studies may not be replicated in future studies; (4) the
possibility that we may not be able to raise additional capital on
terms and on a timeframe acceptable to us, if at all; (5)
uncertainties relating to our patents and proprietary rights; and
(6) other risks identified in our Securities and Exchange
Commission filings. We caution readers not to place undue reliance
on any forward-looking statements which speak only as of the date
they are made. We disclaim any obligation to publicly update or
revise any such statements to reflect any change in expectations or
in events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Contact: Lisa Gordon VP of Business Development Advanced Magnetics,
Inc. (617) 497-2070, x3024 DATASOURCE: Advanced Magnetics, Inc.
CONTACT: Lisa Gordon, VP of Business Development of Advanced
Magnetics, Inc., +1-617-497-2070, ext. 3024 Web site:
http://www.advancedmagnetics.com/
Copyright
Advance Magnetic (AMEX:AVM)
Historical Stock Chart
From Apr 2024 to May 2024
Advance Magnetic (AMEX:AVM)
Historical Stock Chart
From May 2023 to May 2024